The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD1386 in healthy male volunteers.
Study Type
INTERVENTIONAL
Allocation
NA
Masking
NONE
Enrollment
6
1 dose of oral solution
Research Site
Macclesfield, CHESHIRE, United Kingdom
Excretion (rate+extent) of radioactivity in urine+faeces following oral administration of [14C]AZD1386
Time frame: Until >90% of predicted total radioactivity has been recovered
Pharmacokinetics of total radioactivity in plasma + unchanged AZD1386 in plasma Metabolite profile in plasma+excreta
Time frame: Predose, + postdose 0.5h, 1h, 2h, 4h, 6h, 8h, 12h, 24h, 48h, 72h, 96h, 120h, 144hPredose + postdose 1h, 4h, 8h, 24h for excreta from predose (baseline) + postdose from 0h continously until 144h
AZD1386 metabolites in plasma+excreta if feasable
Time frame: Predose, 1h, 4h, 8h 24h
Safety + tolerability of AZD1386
Time frame: Predose, 2h, 6h, 12h, 24h, 48h, 168h
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.